Archive: 27/11/2018
Phase 3 trial shows lanadelumab to be effective in reducing hereditary angioedema attacks
A phase 3 clinical trial led by a Massachusetts General Hospital (MGH) physician, finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema (HAE)—a rare, potentially life-threatening ...
Nov 27, 2018
Personalised heart models could improve cardiac care
Groundbreaking computer models that simulate the workings of individual patients' hearts could boost treatment of a common cardiac condition that affects a million people in the UK and countless more worldwide.
Nov 27, 2018
10% of bowel cancer patients can wait more than a year to start treatment
It can take up to a year for some bowel cancer patients in the UK to start treatment, according to international research co-ordinated by Cancer Research UK and published in the BMJ Open today.
Nov 27, 2018